Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 64 Publications

13 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MYjDfZRwfG:6aXOgRZN{[Xl? MVyxNEBvVQ>? MUm3NkBp MmD2SG1UVw>? NVfleZJjWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MVeyOFkxODh5Mx?=
HT-29 NX7SXm9ES3m2b4TvfIlkKEG|c3H5 NXfjPJJ2OTBibl2= M4jhbFczKGh? MoXISG1UVw>? NFHzdFlRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= MYmyOFkxODh5Mx?=
HT-29 NFfIT5hEgXSxdH;4bYMhSXO|YYm= NEHPZXoyOCCwTR?= MmnXO|IhcA>? MmLTSG1UVw>? NUDQOVI4WG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? NYfzcFQ2OjR7MEC4O|M>
PC3 M3TlXmtqdmG|ZTDBd5NigQ>? M1;pdFExOCCwTR?= NIjJXWYyKGh? M3;iUmROW09? M{nz[HBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u NH;IRnEzOTl5OE[4Ny=>
PC3 M{mzOmtqdmG|ZTDBd5NigQ>? M4mwZVExOCCwTR?= NU\QbZpDOSCq MmLTSG1UVw>? MVPEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NYPGW3BSOjF7N{i2PFM>
PC3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGxMlUh|ryP MoLBNUBp NH3sOmJFVVOR MkHaTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P M2HtW|IyQTd6Nkiz
HEK293 M2T5PWZ2dmO2aX;uJGF{e2G7 NUnJb5EzOTByIH7N NGTK[|k5KGh? Mm\NSG1UVw>? M3ftT2lvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= MXWyNVU{QTNyMR?=
BT-20 NEnoWnhMcW6jc3WgRZN{[Xl? M3;BdFIxKM7:TR?= MoL1SG1UVw>? M33rZ2Rw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w M{L1bFIyOzV|NUWx
U937 NXPSZVc6SW62aXLhZ5RmemmjbDDBd5NigQ>? MnzGOVAh|ryP MVm0PEBp MkTPSG1UVw>? MXPJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? M3qyblIyOTR{MUC2
U937 MlniRY51cWKjY4TldolidCCDc4PhfS=> MnPVOVAh|ryP MVK0PEBp M4CwNmROW09? MojySI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? M2GzfFIyOTR{MUC2
U937 M{jROWFvfGmkYXP0[ZJq[WxiQYPzZZk> M2jUfVUxKM7:TR?= MXS0PEBp NFPmOo5FVVOR NUHpOVA6TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? NFPuXnEzOTF2MkGwOi=>
MCF-7 M1;PTWF2fG:yaHHnfUBCe3OjeR?= MmfQN|Ahdk1? M3Ox[|QhcA>? NXjRPGtqTE2VTx?= NEn2coVKdmS3Y3XzJIF2fG:yaHHnfS=> NFP0T3IzODB{OEGzOC=>
U87MG MojyT4lv[XOnIFHzd4F6 M{HxTlEh|ryP NY\2U|l3PiCq NVXtV4NQTE2VTx?= MkTaVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? NVKzfXZsOTl6NEi0NFQ>
U87MG NV70UnFsU2mwYYPlJGF{e2G7 NW\mR2xHOSEQvF2= MmnGOkBp NFfCS49FVVOR MX;Qc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= MV:xPVg1QDRyNB?=
U87MG NX\pPYxjU2mwYYPlJGF{e2G7 Mn7XNUDPxE1? MXq2JIg> NXTJcW55TE2VTx?= MWTEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M1zFO|E6QDR6NEC0
U87MG M2LBO2tqdmG|ZTDBd5NigQ>? MmfLNUDPxE1? MmDJOkBp NHHSTIxFVVOR MnnFSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v NGS4T4oyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb Ml;TRZV1d3CqYXf5JGF{e2G7 NHfOZoExNjJizszN MWCyOEBp M2PYeWROW09? M174b2lv\HWlZYOgZZV1d3CqYXf5 MlrhNVg{QTF7NEm=
COS7 cells expressing EGFP-LC3 MXPBeZRweGijZ4mgRZN{[Xl? NI\tVHAxNjJizszN NU\JeZN{OjRiaB?= NWj5WZI2TE2VTx?= NHzpdYJKdmS3Y3XzJIF2fG:yaHHnfS=> M{jXRVE5OzlzOUS5
H4 M{H2fWZ2dmO2aX;uJGF{e2G7 MlPkNE4zKM7:TR?= M{fweFI1KGh? NXjs[mI{TE2VTx?= M4DOTmlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> M{H2d|E5ODJ2NUi0
HeLa M1:z[mZ2dmO2aX;uJGF{e2G7 NFK4dWEyODBibl2= NEnpOng{PiCq MlLNSG1UVw>? NXXUU|JFUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? MoixNVc2PjN|OEW=
HeLa M{jOfGZ2dmO2aX;uJGF{e2G7 M3nLRVExOCCwTR?= MWKzOkBp M3iwfWROW09? MVLJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> MXyxO|U3OzN6NR?=
HeLa NYLndm9FTnWwY4Tpc44hSXO|YYm= MXOxNFAhdk1? MUGzOkBp NFLC[pFFVVOR M1nyO2lv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> MVqxO|U3OzN6NR?=
SYF NXTsWXNLTnWwY4Tpc44hSXO|YYm= NV;sVpB{OTByIH7N NGnFe24zPCCq MnXoSG1UVw>? M1fLUGlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> M4X3XlE4PTZ|M{i1
SYF M2\iOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHQNVAxKG6P NXrkTYFiOjRiaB?= M4rMSWROW09? NVzVeWp4UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> MnvhNVc2PjN|OEW=
HEK293T M2P3U2FvfGm4aYLhcEBCe3OjeR?= M1G2PVEhdk1? M1PyR|Qh\A>? MVvEUXNQ NITGfW5KdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> MWOxO|Q5PTVyMR?=
HEK293T MWjBcpRqfmm{YXygRZN{[Xl? M{jsUFEhdk1? NFX5c3U1KGR? M4fNcmROW09? MWXJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= MUexO|Q5PTVyMR?=
PBMC NFXzWYJHfW6ldHnvckBCe3OjeR?= NIXkeZoyKG6P NG\xN2IyPCCm NUflSHc{TE2VTx?= MXTS[YR2[2W|IFPDVlUh\GWwc3n0fS=> NIftUnUyPzR6NUWwNS=>
PBMC NE\tNGRHfW6ldHnvckBCe3OjeR?= M1zPcVEhdk1? NYTEbGFkOTRiZB?= NHHmUnBFVVOR MWrEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> M1vXZVE4PDh3NUCx
HEK293 cells M2DrPWtqdmG|ZTDBd5NigQ>? NEXyN5o2OCCwTR?= M3m1SlQ2KG2rbh?= NHuxcmhFVVOR NWiwSGkyUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= MlW1NVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MkewSpVv[3Srb36gRZN{[Xl? M17EPFExOCCwTR?= MYO0JIg> NFnBd3RFVVOR NULLboF6UW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NHjD[mIyPzF{OEK2Ni=>
Human mixed lymphocyte NILCUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuwS5FPPSCwTR?= M{\IcWROW09? NELablRKSzVyPUGuOkBvVS5? MVyxOlE5PTh4NR?=
Lewis rat lymph node cells MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTJbWY2KM7:TR?= MlPhSG1UVw>? M3LyTGlEPTB;Mj62JO69VQ>? NF7SZXYyPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXLXnAyOCCwTR?= MnTVO|IhcA>? NVTMVm9oTE2VTx?= MWnJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P MXSxNFAzOTl2OB?=
MRK-nu-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfFe4JKSzVyPUCuPFQ2KHCP Ml21V2FPT0WU
OCUB-M Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLpTWM2OD13LkK0JJBO NUe2UlNwW0GQR1XS
SF539 NHzBUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC3Z5JiUUN3ME2xNU43KHCP NYXMNllEW0GQR1XS
ES4 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\RZXBKSzVyPUKxMlUheE1? NEnYVnBUSU6JRWK=
RL95-2 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HHZWlEPTB;MUC3JJBO MYPTRW5ITVJ?
LC-2-ad MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\DTWM2OD12MkOgdG0> MYPTRW5ITVJ?
Daudi M13tPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13HWmlEPTB;NEO0JJBO MUDTRW5ITVJ?
NTERA-S-cl-D1 M1\OWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP6TWM2OD12NEOgdG0> NIqx[nBUSU6JRWK=
OS-RC-2 NIf6bm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPpTWM2OD14NUKgdG0> MU\TRW5ITVJ?
VA-ES-BJ MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4niZWlEPTB;N{KzJJBO NE\KXppUSU6JRWK=
GR-ST MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHiTWM2OD16NE[gdG0> NHHpS4hUSU6JRWK=
SW872 NEjvNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTh2NjDwUS=> NYrCNVFHW0GQR1XS
NOS-1 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHwUHhZUUN3ME24O|EheE1? MXrTRW5ITVJ?
MC116 M{XP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETYTJVKSzVyPUm4OUBxVQ>? MYDTRW5ITVJ?
NCI-H1355 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwMEGgcm0> MnPSV2FPT0WU
RPMI-8226 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nmUWlEPTB;MT6xPUBvVQ>? M3fxS3NCVkeHUh?=
TE-15 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL3TWM2OD1zLkO2JI5O NGXkTYlUSU6JRWK=
Ramos-2G6-4C10 M1HsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELwXGJKSzVyPUGuOFYhdk1? M2DUTXNCVkeHUh?=
KU812 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PYfmlEPTB;Mj6wNUBvVQ>? NGTWW4VUSU6JRWK=
EW-1 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\XTWhPUUN3ME2yMlE4KG6P NVzpe41OW0GQR1XS
KS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rtWGlEPTB;Mj60OUBvVQ>? M{\vN3NCVkeHUh?=
SK-LMS-1 NW\ScVg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLZZ3ZMUUN3ME2yMlQ6KG6P M4\kbXNCVkeHUh?=
TGBC1TKB M4\n[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjsbo1KSzVyPUKuOlkhdk1? M1LldHNCVkeHUh?=
TE-6 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG3V3Y4UUN3ME2yMlc4KG6P MXLTRW5ITVJ?
ETK-1 M1vCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwOEKgcm0> M1z4e3NCVkeHUh?=
BE-13 NHe3fWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfZbnJKSzVyPUKuPVkhdk1? MljpV2FPT0WU
A3-KAW NV7tWXZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETDR4FKSzVyPUKuPVkhdk1? NEexT2pUSU6JRWK=
TE-10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PiXWlEPTB;Mz6zJI5O NF\WOHBUSU6JRWK=
DOHH-2 NX7Oe4tDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwM{Wgcm0> NXz3bZAyW0GQR1XS
ES6 NHvpSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwNEOgcm0> MXjTRW5ITVJ?
OPM-2 NYfvbohJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTRwMUWgcm0> M4O4RXNCVkeHUh?=
SH-4 NYjWPJIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne2TWM2OD12LkO0JI5O NEH5PZNUSU6JRWK=
NB13 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrXVVlKSzVyPUSuN|Yhdk1? NUnNU5BtW0GQR1XS
HUTU-80 NWXzdZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULUOllSUUN3ME20MlQzKG6P M3\a[nNCVkeHUh?=
CCRF-CEM MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzXTWM2OD12Lkm0JI5O NV7YWGllW0GQR1XS
TGBC24TKB NH:xfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fjemlEPTB;NT61NUBvVQ>? MVnTRW5ITVJ?
697 M130Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3STWM2OD14LkK4JI5O NHTS[I1USU6JRWK=
J-RT3-T3-5 M1;1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTZwNE[gcm0> MnrKV2FPT0WU
KALS-1 M1nWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;lZW9KSzVyPU[uOVYhdk1? MUHTRW5ITVJ?
no-10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjkOHJNUUN3ME23MlI6KG6P NXu5dHlDW0GQR1XS
SK-NEP-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jTTmlEPTB;OD63PUBvVQ>? MVfTRW5ITVJ?
L-540 NF75ZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTjcmpKUUN3ME2xNE41OiCwTR?= NHjXXGZUSU6JRWK=
JiyoyeP-2003 NVTC[3ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTlWIxKSzVyPUGwMlk1KG6P MV;TRW5ITVJ?
HH MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETnZmdKSzVyPUGxMlM6KG6P NVLWdYMyW0GQR1XS
SR M4GzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFzLkS1JI5O MnSyV2FPT0WU
QIMR-WIL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFzLki1JI5O NHLpTIFUSU6JRWK=
A4-Fuk NXvDSXNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PwPWlEPTB;MUOuNVIhdk1? NYK1Z2llW0GQR1XS
CESS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDsTWM2OD1zMz6xN{BvVQ>? NYTxT3BKW0GQR1XS
KE-37 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHDZXlKUUN3ME2xOk4xPyCwTR?= NWPKWXVKW0GQR1XS
SK-UT-1 NHP1UXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[4SGlEPTB;MU[uPFEhdk1? MkfvV2FPT0WU
SIG-M5 NXOxWIRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\BeFRNUUN3ME2xO{4zPSCwTR?= MWjTRW5ITVJ?
HT NEHmNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnUSYZKSzVyPUG3MlYhdk1? Ml6xV2FPT0WU
DEL NFnQc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3niZmlEPTB;MUeuPVkhdk1? MVnTRW5ITVJ?
SK-PN-DW M3Htb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvlPFFuUUN3ME2yNE4zOyCwTR?= M4S3[nNCVkeHUh?=
RPMI-8402 M3v3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:ydGlEPTB;MkGuO|chdk1? NX7tfJFSW0GQR1XS
RPMI-6666 NXP1VWJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPrTWM2OD1{ND60NkBvVQ>? M1jvN3NCVkeHUh?=
NCI-H720 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfVUVV[UUN3ME2yOU41OSCwTR?= NUmxbVFUW0GQR1XS
EW-16 NGriZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUThN5ZXUUN3ME2yOk45PyCwTR?= NF;WNIxUSU6JRWK=
BL-70 NYW2cYJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX5bZlKSzVyPUK4MlM5KG6P NU\hVGRRW0GQR1XS
SF126 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHRTWM2OD1|MD6zPEBvVQ>? MVTTRW5ITVJ?
BC-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGW2fGJKSzVyPUOxMlI3KG6P NFzZVJhUSU6JRWK=
MHH-PREB-1 MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X3N2lEPTB;M{KuOFQhdk1? NF\yR3BUSU6JRWK=
A101D MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Tjb2lEPTB;M{KuOlIhdk1? MlL5V2FPT0WU
NMC-G1 M3\qU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzSTWM2OD1|Mz62O{BvVQ>? NFfueYtUSU6JRWK=
LB1047-RCC NVLF[WM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTN2Lk[5JI5O MYrTRW5ITVJ?
EM-2 M3PiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\XUFRYUUN3ME2zPE42OyCwTR?= NHvNbWRUSU6JRWK=
COLO-684 M{XwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN7Lkigcm0> MYDTRW5ITVJ?
Becker NH7JTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTRzLkC1JI5O NXW2PI5iW0GQR1XS
BL-41 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTR|Lk[2JI5O NV;yWXlKW0GQR1XS
MDA-MB-134-VI MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj3[|FPUUN3ME20OE4xOiCwTR?= MX\TRW5ITVJ?
L-363 NYf4e2sxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fsfGlEPTB;NESuO|Mhdk1? M{f2VXNCVkeHUh?=
ECC4 NUfVbHF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHMcIczUUN3ME20OE44QCCwTR?= NX\hfnZKW0GQR1XS
A388 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjHVWtKSzVyPUS0MlgzKG6P NUTD[Y1XW0GQR1XS
HEL NFTRNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;3d2lEPTB;NEmuO|khdk1? NXv2XoNLW0GQR1XS
RKO NX7uZm4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjyZolzUUN3ME21NE4zQSCwTR?= NFzIN29USU6JRWK=
KINGS-1 M3XST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq2Z21KSzVyPUWxMlU2KG6P M1fuWnNCVkeHUh?=
EB-3 NVHafId[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTV{Lk[3JI5O M1zY[HNCVkeHUh?=
ARH-77 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;wd2lEPTB;NUKuPEBvVQ>? MoLTV2FPT0WU
GCIY M4TnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzUOlZKSzVyPUWzMlQ3KG6P M1zSWnNCVkeHUh?=
NCI-H1304 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrKTWM2OD13Nz6yNkBvVQ>? M3PVNXNCVkeHUh?=
KARPAS-299 NInrbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnNfmd{UUN3ME22NU45OiCwTR?= M4T3bHNCVkeHUh?=
IA-LM NF33Z|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzNTWM2OD14OD6xN{BvVQ>? MojVV2FPT0WU
GI-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKxVFdKSzVyPUewMlM6KG6P MlvLV2FPT0WU
TE-11 M3LtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLwS|NRUUN3ME23O{4yPyCwTR?= M3PjfXNCVkeHUh?=
LS-411N NXvXO2JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TicmlEPTB;N{euOVchdk1? MmjpV2FPT0WU
no-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTh|LkK0JI5O NYL4[WFqW0GQR1XS
MV-4-11 NYXNcpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTh|LkezJI5O MnnWV2FPT0WU
BV-173 NH7ZNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTh|Lkm3JI5O MknHV2FPT0WU
CMK MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofpTWM2OD16ND6xOkBvVQ>? M{LMSHNCVkeHUh?=
LC4-1 NEe5b29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLJZZE1UUN3ME24Ok44OiCwTR?= MUnTRW5ITVJ?
COR-L279 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXlXVFDUUN3ME24O{4zPSCwTR?= MX;TRW5ITVJ?
NCI-H209 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P3UmlEPTB;OEeuOFEhdk1? MWrTRW5ITVJ?
Raji NHH5eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljGTWM2OD16OT63NkBvVQ>? NX;iUmY{W0GQR1XS
LB996-RCC M4PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\UcZVIUUN3ME25N{41OyCwTR?= NWnsfHU1W0GQR1XS
NCI-H526 NXjvZmNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MniwTWM2OD17Mz61PUBvVQ>? MmS5V2FPT0WU
KGN NUO5VIFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknWTWM2OD17Nj6yPUBvVQ>? MYLTRW5ITVJ?
MOLT-4 M1\HOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW4TWM2OD17Nj63PUBvVQ>? MVHTRW5ITVJ?
PF-382 NXLhZVlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTl4Lke5JI5O NHHkb4RUSU6JRWK=
BC-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTl7LkG4JI5O MWTTRW5ITVJ?
KARPAS-422 NXL3dYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[xOmlEPTB;MUCyMlA6KG6P NFf5SIdUSU6JRWK=
SBC-1 NWS3T|NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;HTWM2OD1zMEeuO|Uhdk1? MoHLV2FPT0WU
LC-1F MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W4cWlEPTB;MUC4MlA2KG6P NX6xZopkW0GQR1XS
GB-1 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ToXWlEPTB;MUC5MlAzKG6P NEPiOGJUSU6JRWK=
SNB75 NIfTSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PwTGlEPTB;MUG5MlY6KG6P NHroN3VUSU6JRWK=
BB65-RCC NGPtcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fSXWlEPTB;MUG5Mlk{KG6P NWjnTmVIW0GQR1XS
NCI-N87 M1jvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrySFRKSzVyPUGyNU46QCCwTR?= NFrhPVlUSU6JRWK=
IST-MEL1 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPWbYRHUUN3ME2xNlIvOzhibl2= MUnTRW5ITVJ?
HOP-62 M3znWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[wZmlEPTB;MUK2Mlg6KG6P M1vMc3NCVkeHUh?=
ACN NFLQTZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzTTWM2OD1zNE[uO|Uhdk1? MlfGV2FPT0WU
DMS-114 NWK2eZBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf4SoJVUUN3ME2xOVAvPjdibl2= MVzTRW5ITVJ?
MLMA Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXwTWM2OD1zNUmuPFghdk1? NVTZZnBMW0GQR1XS
HT-144 NX;MOGpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qyUGlEPTB;MU[1MlQ{KG6P MmLGV2FPT0WU
C2BBe1 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF4Nz63OkBvVQ>? NEXXd2hUSU6JRWK=
L-428 NGTQWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HMdGlEPTB;MUe3Mlchdk1? MXHTRW5ITVJ?
DU-4475 MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF6Nz62PEBvVQ>? NWn0e25NW0GQR1XS
CP67-MEL MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF7OT6zPEBvVQ>? NV\uO4duW0GQR1XS
MEG-01 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjP[XJKSzVyPUKwNU46PiCwTR?= MoTyV2FPT0WU
IST-SL2 NGf5epZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjkTWM2OD1{MEiuOlMhdk1? NEf6cmNUSU6JRWK=
ES8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jwU2lEPTB;MkK1Mlk1KG6P M4fPOHNCVkeHUh?=
COLO-800 M4KyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLpT3lKSzVyPUKzOU4zQCCwTR?= NYDzRYpJW0GQR1XS
MFH-ino NFLJbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJ|NT64OEBvVQ>? Mnu0V2FPT0WU
OVCAR-4 NED2TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;neIFKSzVyPUKzO{4zPCCwTR?= MY\TRW5ITVJ?
PSN1 M2DSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ2Mj63NUBvVQ>? Mn3CV2FPT0WU
EW-12 NHj5NoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLsTWM2OD1{NEOuNUBvVQ>? NEHGe5pUSU6JRWK=
HCC1599 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITGO5FKSzVyPUK2NU41PyCwTR?= MmLoV2FPT0WU
SJSA-1 NYHIcGd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkiwTWM2OD1{N{GuOFYhdk1? NU[4O5RNW0GQR1XS
ST486 NYTTdYg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGybYVKSzVyPUK5Ok4yPCCwTR?= NYHTNFhiW0GQR1XS
NOMO-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjFeYt6UUN3ME2zNFAvOjFibl2= NFy1PXZUSU6JRWK=
MN-60 NI\CSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G2ZWlEPTB;M{C1MlMzKG6P MlezV2FPT0WU
HCC1187 M2r2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXycm5qUUN3ME2zNFcvOjVibl2= MnXwV2FPT0WU
SW982 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KxdGlEPTB;M{G0Mlc2KG6P MYHTRW5ITVJ?
LB647-SCLC NFvxeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:3UmlEPTB;M{K4MlcyKG6P NVfyd49HW0GQR1XS
HC-1 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETmeFZKSzVyPUOzOU42KG6P M161NnNCVkeHUh?=
EHEB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUiyc5hLUUN3ME2zN|cvPTJibl2= MmDkV2FPT0WU
TUR MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLsTWM2OD1|NkOuPVUhdk1? MWHTRW5ITVJ?
LU-139 NGDDXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljTTWM2OD1|N{iuNFIhdk1? MluyV2FPT0WU
NB1 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm1bmNKSzVyPUO4OE41PSCwTR?= NFm4cJpUSU6JRWK=
BB30-HNC NGj3cYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jiWGlEPTB;M{i4MlMzKG6P MVzTRW5ITVJ?
HAL-01 NIq4OnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1roZ2lEPTB;M{i5MlI3KG6P MVfTRW5ITVJ?
K5 NFu0fZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfmc|VyUUN3ME20NVEvOzdibl2= NEXTPIhUSU6JRWK=
MZ2-MEL NY\WeoQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\0[|JKSzVyPUSxN{43PCCwTR?= NYHITm5pW0GQR1XS
RXF393 NGLJWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[2bFZKSzVyPUSxOk41PSCwTR?= MUDTRW5ITVJ?
NCI-H1648 NUCwbGRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTRzNz61N{BvVQ>? NE\CfmlUSU6JRWK=
TE-12 M37oZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXlTWM2OD12M{SuNlYhdk1? NWXHPIsxW0GQR1XS
EoL-1- MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjsVZo{UUN3ME20N|cvQThibl2= M3nRfnNCVkeHUh?=
JAR NH7pboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR|OD62NkBvVQ>? MljiV2FPT0WU
DSH1 NUDIN5N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjDTWM2OD12NUiuPVEhdk1? NHL2O2tUSU6JRWK=
NCI-H187 NYHTcmdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTJTWM2OD12NkKuPFEhdk1? Mnm1V2FPT0WU
HCE-4 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13N[GlEPTB;NEe3MlY3KG6P M2\lV3NCVkeHUh?=
8-MG-BA M4HG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfLTWM2OD13OEGuOVIhdk1? M2XGWXNCVkeHUh?=
KLE MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTuTHJKSzVyPUW4OU4zKG6P MleyV2FPT0WU
KNS-42 NV7Od2VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof2TWM2OD13OE[uPFEhdk1? NF\sdIJUSU6JRWK=
MSTO-211H MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInZVnpKSzVyPU[wPU44PCCwTR?= NEnBN3pUSU6JRWK=
GDM-1 NX3XO4ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiyVlA3UUN3ME22NVQvODlibl2= M4X3NnNCVkeHUh?=
TE-1 M3zQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnFXVV1UUN3ME22OFYvOTJibl2= MoHjV2FPT0WU
BT-474 M1Lye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L1Z2lEPTB;NkS3MlA3KG6P MlXtV2FPT0WU
KARPAS-45 Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\DU3JKSzVyPU[0O{43KG6P M1ntWHNCVkeHUh?=
MOLT-16 NIqwclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2izbmlEPTB;NkS3Mlk{KG6P MlriV2FPT0WU
KURAMOCHI Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTZ3Nz61NUBvVQ>? MVrTRW5ITVJ?
K-562 NV\xc4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLLTWM2OD14NkmuOVEhdk1? MWLTRW5ITVJ?
EKVX NGO0ZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr5RZp{UUN3ME22O|IvPzFibl2= MlvBV2FPT0WU
GAK NWeyfWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGwZmpzUUN3ME22O|UvOyCwTR?= MWLTRW5ITVJ?
NCI-SNU-5 NUj2VWZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ftOGlEPTB;NkmwMlAyKG6P M13md3NCVkeHUh?=
NCI-H2126 NVvUOJNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTd{Nj64O{BvVQ>? MV3TRW5ITVJ?
CTV-1 NVjHbGFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTd2ND65JI5O NIPKfm5USU6JRWK=
SW962 NFruOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTd2OD60OEBvVQ>? MUHTRW5ITVJ?
MONO-MAC-6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPHcVMzUUN3ME23OVYvQTNibl2= NHGxUo1USU6JRWK=
NCI-H748 M1;jVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;XflVoUUN3ME23OVgvQTlibl2= M4PpdHNCVkeHUh?=
NCI-H524 NFXVd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fhXGlEPTB;N{iwMlc{KG6P MXjTRW5ITVJ?
LS-123 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDINlFJUUN3ME23PVUvPjlibl2= NUjufVF3W0GQR1XS
NB7 NYP5VlJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfTTWM2OD16MUSuNVQhdk1? MknhV2FPT0WU
LS-1034 NHy3UlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP6VIZ1UUN3ME24NlgvQThibl2= NVrTbpFkW0GQR1XS
TE-5 M3;CZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\Zb4FKSzVyPUi4N{42PiCwTR?= M3ruZnNCVkeHUh?=
A704 NFHNV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:zTWM2OD16OUmuNVUhdk1? M4\ZPHNCVkeHUh?=
TK10 NVPGeZY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTlzNj6wN{BvVQ>? MmjnV2FPT0WU
NCI-H345 M3rsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTl2Mz6yNkBvVQ>? NHLGU3JUSU6JRWK=
CGTH-W-1 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTl2OD6xN{BvVQ>? MmHjV2FPT0WU
NCI-H510A M4HJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGeyVVhKSzVyPUm4OU4yOiCwTR?= NYXOU2ViW0GQR1XS
NCI-H1963 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFwMEOyPVIh|ryP M1HlbXNCVkeHUh?=
SCC-3 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwMEO0NVQh|ryP MYfTRW5ITVJ?
EW-11 M3rYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXENXpwUUN3ME2xMlA5PzR|IN88US=> M4LjU3NCVkeHUh?=
CPC-N MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljsTWM2OD1zLkC4PEDPxE1? MXPTRW5ITVJ?
NCI-H1417 M1TLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XZU2lEPTB;MT6xNlI3KM7:TR?= NF;qTVJUSU6JRWK=
DG-75 M4XKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwMU[yPFUh|ryP MnLKV2FPT0WU
HD-MY-Z NEX0OG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwMU[0NVYh|ryP M4fZSHNCVkeHUh?=
ATN-1 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDHdHpRUUN3ME2xMlI3OjB7IN88US=> NVfvb3BHW0GQR1XS
KM-H2 NVHYb2doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTmNIE5UUN3ME2xMlI3PDB6IN88US=> M1jsNHNCVkeHUh?=
NCI-H2081 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTzfZBVUUN3ME2xMlI3PjN5IN88US=> NXK4fZNWW0GQR1XS
HL-60 M1qy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT3VHlKSzVyPUGuNlY6PTlizszN MXjTRW5ITVJ?
DB M4\OV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\IUlVKSzVyPUGuNlczPDJizszN NUHqXo4xW0GQR1XS
NCI-H1522 NETNfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyxcGlKSzVyPUGuNlg5QDdizszN MoLLV2FPT0WU
AM-38 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\WOmlEPTB;MT6zNFczKM7:TR?= NXzTRYFOW0GQR1XS
NCI-H446 NWLMNndLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M164N2lEPTB;MT6zNlEzOSEQvF2= M2e3WnNCVkeHUh?=
SU-DHL-1 M2X5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;TfWNlUUN3ME2xMlMzQDBzIN88US=> NHeyS5ZUSU6JRWK=
NH-12 M{fF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nVV2lEPTB;MT6zOlM4PCEQvF2= M{PiSHNCVkeHUh?=
DMS-79 NFm3WlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUniUplqUUN3ME2xMlM3QDZ4IN88US=> MomyV2FPT0WU
NCI-H716 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDOTWM2OD1zLkO4PVg3KM7:TR?= NGXaXlNUSU6JRWK=
ML-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwNEG1Nlkh|ryP NVO1TIJJW0GQR1XS
NB10 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTYOJRKSzVyPUGuOFY3OzJizszN NET1TXVUSU6JRWK=
ONS-76 NIrQWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfhSnR4UUN3ME2xMlU{PTZ7IN88US=> MY\TRW5ITVJ?
LOUCY MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXvfppzUUN3ME2xMlU1PjV5IN88US=> MkPzV2FPT0WU
SCLC-21H MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS2clczUUN3ME2xMlU5PTh{IN88US=> NUDzN|VLW0GQR1XS
TGW M3L0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jqdmlEPTB;MT62N|k4PSEQvF2= NWTSVXVkW0GQR1XS
LXF-289 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXCbWJWUUN3ME2xMlc{OjZ6IN88US=> NU\3fZM3W0GQR1XS
BB49-HNC NUH5XnozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwN{O1PFYh|ryP M3\3e3NCVkeHUh?=
NCI-H747 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXIV5ZKSzVyPUGuO|U{PDZizszN MXHTRW5ITVJ?
LU-165 M4fTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTjcHg5UUN3ME2xMlg1QTh4IN88US=> MnnWV2FPT0WU
OMC-1 M2\lRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;LTGlEPTB;MT65OVA3PiEQvF2= NYnPS3N4W0GQR1XS
RCC10RGB MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwOUW4NVch|ryP M3nuWnNCVkeHUh?=
SW684 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwOU[wPVkh|ryP M1TiZXNCVkeHUh?=
TE-8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj6TWM2OD1{LkC1OVU6KM7:TR?= NEXxTVdUSU6JRWK=
SK-N-DZ M4TiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTDTWM2OD1{LkGzNlc1KM7:TR?= MV7TRW5ITVJ?
EVSA-T MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTwTWM2OD1{LkG3N|E2KM7:TR?= NHTuVlBUSU6JRWK=
KASUMI-1 NHLhUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjLWWhKSzVyPUKuNVg5OTVizszN NYjMWpdDW0GQR1XS
NKM-1 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX5TlFIUUN3ME2yMlI2PDd{IN88US=> M4ryOHNCVkeHUh?=
CAL-148 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfa[lZKSzVyPUKuN|M3OTRizszN NH61Om5USU6JRWK=
NCI-H64 M4PUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jGb2lEPTB;Mj6zOFI{OiEQvF2= MWHTRW5ITVJ?
KNS-81-FD MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{izUWlEPTB;Mj6zOlYzKM7:TR?= NH3CcmNUSU6JRWK=
KM12 NV7jN5B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluyTWM2OD1{LkSwPFM6KM7:TR?= MnnoV2FPT0WU
SW954 NH3R[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvRS2xvUUN3ME2yMlQ4Pzd7IN88US=> NHPLRZlUSU6JRWK=
NCI-H1395 NXvY[nBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfITWM2OD1{LkWyOlQ2KM7:TR?= NH\vUlBUSU6JRWK=
DJM-1 NH\OdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnxSlN6UUN3ME2yMlYxPjNizszN NFrxUY9USU6JRWK=
COLO-668 NX;TVo85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M176OGlEPTB;Mj64NlY6PSEQvF2= MnXJV2FPT0WU
NCI-H1436 M17wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTaTWM2OD1{Lki1OlE2KM7:TR?= M1jIdnNCVkeHUh?=
LB2241-RCC MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT4TWM2OD1{Lki2PFM6KM7:TR?= MmLzV2FPT0WU
GT3TKB NEKyblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LaNWlEPTB;Mj64PVA2PSEQvF2= MoPlV2FPT0WU
COLO-824 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP3[mFVUUN3ME2yMlg6PzZ6IN88US=> M{Hld3NCVkeHUh?=
ES1 NHPreHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTIVIxzUUN3ME2yMlg6QDd7IN88US=> NHvPbHdUSU6JRWK=
LB771-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTETWM2OD1{LkmwPVQ3KM7:TR?= NFjmVYlUSU6JRWK=
GI-ME-N M2X0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTNwMEC5NFQh|ryP NWfwUmF3W0GQR1XS
NALM-6 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jYR2lEPTB;Mz6wNFk{OyEQvF2= M4nobHNCVkeHUh?=
LU-134-A NIjkNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTNwMEW0NlUh|ryP M3XEdnNCVkeHUh?=
DMS-153 NEjVcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LHR2lEPTB;Mz6wOVgzPCEQvF2= NX7ZVY13W0GQR1XS
MZ1-PC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXSV|IzUUN3ME2zMlA6ODd6IN88US=> MYfTRW5ITVJ?
NCI-H1155 M3PzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\Y[29KSzVyPUOuNVE3OSEQvF2= MXnTRW5ITVJ?
CAS-1 NFvN[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTGeGhMUUN3ME2zMlE{PzB5IN88US=> M2DaOnNCVkeHUh?=
D-502MG Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwMUSzPUDPxE1? MmX6V2FPT0WU
NCI-H2141 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTheZNQUUN3ME2zMlE4PDV{IN88US=> NEPKeo5USU6JRWK=
NB6 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S1WWlEPTB;Mz6xPFI2QSEQvF2= NVjqRlJuW0GQR1XS
NCCIT MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNwMkG4NFkh|ryP NELHNoNUSU6JRWK=
NB69 NIDkV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHIZ|hKSzVyPUOuN|E5QTFizszN M1jjO3NCVkeHUh?=
JVM-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W5[2lEPTB;Mz6zOlQ{OyEQvF2= NHLyRodUSU6JRWK=
K052 M2jYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17C[mlEPTB;Mz6zO|k3QCEQvF2= MYDTRW5ITVJ?
HCC2157 NYL0[JF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HYR2lEPTB;Mz61N|IzQCEQvF2= NIj5SFRUSU6JRWK=
KMOE-2 M{nCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNwNUSyOFIh|ryP NUD4dY9pW0GQR1XS
SF268 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnewTWM2OD1|LkexOVU1KM7:TR?= NWX6T2xkW0GQR1XS
CHP-126 NIP4TXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLNN2FNUUN3ME2zMlc3PDV6IN88US=> NHjOe3lUSU6JRWK=
CP66-MEL Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonYTWM2OD1|Lke5NFk1KM7:TR?= M{\ySXNCVkeHUh?=
NCI-H69 M{T3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX5TWM2OD12LkCxPVM3KM7:TR?= Mon6V2FPT0WU
A253 NGjObZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K4OmlEPTB;ND6wNlExOSEQvF2= M4K3R3NCVkeHUh?=
NB14 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrkTWM2OD12LkGwOFc6KM7:TR?= NFT6OGFUSU6JRWK=
NCI-H1694 MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSwTWM2OD12LkGzNVEzKM7:TR?= NWXDcI0xW0GQR1XS
NCI-H2196 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDmWYVKSzVyPUSuNVcyPjlizszN MYfTRW5ITVJ?
TE-9 MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILBWnlKSzVyPUSuNVc2QDJizszN M1fRR3NCVkeHUh?=
D-283MED NV3uXHlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf0cXpKSzVyPUSuNVg5PCEQvF2= M{DYOXNCVkeHUh?=
OCI-AML2 MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvDWpRXUUN3ME20MlE6PDh7IN88US=> Mof6V2FPT0WU
D-263MG MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTRwMkK5OlEh|ryP MW\TRW5ITVJ?
MPP-89 NHHtdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvTWM2OD12LkK3N|A1KM7:TR?= Mk\ZV2FPT0WU
LAMA-84 NH\pR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HyV2lEPTB;ND6zNFQzOSEQvF2= MkC3V2FPT0WU
LB373-MEL-D MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvTTWM2OD12LkO2O|g6KM7:TR?= M1X0OXNCVkeHUh?=
UACC-257 NVrIb5hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LxemlEPTB;ND6zPVU{PCEQvF2= NIjNRmFUSU6JRWK=
MC-CAR M2HQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTRwNEO5PUDPxE1? NHnQRmJUSU6JRWK=
COLO-320-HSR MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Qe2lEPTB;ND60OFQzPyEQvF2= MU\TRW5ITVJ?
P30-OHK MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPOTWM2OD12Lk[2OVgyKM7:TR?= M37N[HNCVkeHUh?=
UACC-812 M{\Jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTRwNkmxOlEh|ryP M1Ho[HNCVkeHUh?=
CTB-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\5VWlEPTB;ND63NVU2PSEQvF2= MWjTRW5ITVJ?
ALL-PO NVSzdZhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTRwOESwO|ch|ryP MkTjV2FPT0WU
SK-MEL-2 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PyZ2lEPTB;ND64Olk2PSEQvF2= NG\te3VUSU6JRWK=
TC-YIK M1L2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DqcGlEPTB;ND65O|k1OiEQvF2= NXz0T3J{W0GQR1XS
NCI-H1882 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXFNXRuUUN3ME21MlAzODBzIN88US=> M{LCd3NCVkeHUh?=
MHH-CALL-2 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne3TWM2OD13LkC1NFQzKM7:TR?= M2fGdHNCVkeHUh?=
U-87-MG M2PTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zZ[mlEPTB;NT6wPVQ3PiEQvF2= MoDKV2FPT0WU
NCI-H1092 NE\DXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDzV5FKSzVyPUWuNlY2PTVizszN NIXIe2VUSU6JRWK=
TE-441-T MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfhTWM2OD13LkK3PFIh|ryP NHvkZ3hUSU6JRWK=
SK-MEL-1 NYWxWFdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTVwMkmwOFQh|ryP NFf4T3dUSU6JRWK=
EW-22 NWLNdnF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWwTWM2OD13LkK5OFY3KM7:TR?= MWnTRW5ITVJ?
MZ7-mel MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO2RYJKSzVyPUWuOFA3QTFizszN NVjwW5JtW0GQR1XS
LP-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq0TWM2OD13LkSxNlkyKM7:TR?= NGjIe29USU6JRWK=
NCI-SNU-16 M4PHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLFVog{UUN3ME21MlY1ODd2IN88US=> NXnsOGYxW0GQR1XS
LU-65 NX[4T2kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M134dGlEPTB;NT63OlM4OyEQvF2= NH7US5RUSU6JRWK=
CW-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITpWlNKSzVyPUWuPFU6PTlizszN MmS3V2FPT0WU
WSU-NHL M2\CRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HaSWlEPTB;NT65OVE4PCEQvF2= M1jaZ3NCVkeHUh?=
IST-MES1 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTYWFlEUUN3ME21Mlk2PDR|IN88US=> NXPFVYdVW0GQR1XS
U-266 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LMe2lEPTB;NT65PFIxOiEQvF2= NUiweJRQW0GQR1XS
TALL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvYTWQ{UUN3ME22MlE1Pjh6IN88US=> MXTTRW5ITVJ?
Calu-6 M2\aUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTEXmw6UUN3ME22MlE2OzF4IN88US=> NVXa[VFMW0GQR1XS
MMAC-SF NVvuS|NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS0TWM2OD14LkG4OVU3KM7:TR?= MnvYV2FPT0WU
NCI-H82 NYDzVms6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jWUmlEPTB;Nj6yNFQ5QSEQvF2= M3i5OHNCVkeHUh?=
RS4-11 M330N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ZeGlKSzVyPU[uNlU5QTdizszN MV7TRW5ITVJ?
SNU-C2B M2XsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTZwNEC5Olkh|ryP NGHHepNUSU6JRWK=
BOKU NILIXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Tuc2lEPTB;Nj60O|U6PyEQvF2= M1vNZ3NCVkeHUh?=
C8166 NVfwTGkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofHTWM2OD14LkW1PVEzKM7:TR?= NGPWflhUSU6JRWK=
D-247MG Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HpNGlEPTB;Nz6wOFM1PyEQvF2= NYDpWIkyW0GQR1XS
EW-18 NX:xZ21vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\RTWM2OD15LkC3NlkzKM7:TR?= M4f0O3NCVkeHUh?=
KG-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\TTWM2OD15Lk[yO|M5KM7:TR?= NWfXd2xrW0GQR1XS
REH MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHXNpp5UUN3ME23MlY5OTB7IN88US=> M1rsZ3NCVkeHUh?=
U-698-M MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTdwOESzNVUh|ryP M{nWd3NCVkeHUh?=
KP-N-RT-BM-1 M4TVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn25TWM2OD15LkmzNFI6KM7:TR?= NHLPWYpUSU6JRWK=
MS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHyR2VKSzVyPUeuPVYxPDFizszN M4TYeXNCVkeHUh?=
SNU-C1 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fh[WlEPTB;Nz65PFE6OiEQvF2= NEO4PZRUSU6JRWK=
SK-MM-2 NVewS4xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHqTWM2OD16LkK2NFY2KM7:TR?= NW\QZ2ZqW0GQR1XS
LAN-6 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLmTGNKSzVyPUiuN|AxODFizszN MVLTRW5ITVJ?
NEC8 NWfmc5huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;yTWM2OD16LkOwOlkyKM7:TR?= MXfTRW5ITVJ?
NCI-H1770 NF3vOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRThwM{iwNFIh|ryP NF6zPIJUSU6JRWK=
D-336MG NUHRdFNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DtUmlEPTB;OD60NFEyPiEQvF2= NIXFN3pUSU6JRWK=
COLO-829 NVHNWZE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRThwNEi4O|kh|ryP M4\MOnNCVkeHUh?=
LS-513 NVPy[I5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L5S2lEPTB;OD61PVU6QSEQvF2= MnfCV2FPT0WU
YT NHjlT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXzSG5mUUN3ME24MlYzPDJ5IN88US=> M{K4[3NCVkeHUh?=
EW-24 Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xrb2lEPTB;OD63OlU1KM7:TR?= NYjBOWpqW0GQR1XS
IST-SL1 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli3TWM2OD16Lki2OVQ{KM7:TR?= NUPNe4dtW0GQR1XS
CA46 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nDXmlEPTB;OD65OVA6QCEQvF2= MkjMV2FPT0WU
NCI-H1838 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnhV4kyUUN3ME24Mlk5PjB{IN88US=> Mk\WV2FPT0WU
NCI-H719 NUnSdIprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHqxWnhKSzVyPUmuNlUzPzlizszN M3TXN3NCVkeHUh?=
HCE-T MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHm3eYxKSzVyPUmuN|A5PTFizszN MoHvV2FPT0WU
A498 NWH4N4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXmTWM2OD17LkO2NVI1KM7:TR?= MWPTRW5ITVJ?
LB831-BLC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\jV2lEPTB;OT63OlUzOSEQvF2= MnPVV2FPT0WU
SKM-1 NXXneI1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jlbmlEPTB;OT64OVk3OyEQvF2= M3HJdnNCVkeHUh?=
THP-1 NHPJbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTlwOU[5NVgh|ryP MY\TRW5ITVJ?
SHP-77 NHK5dYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\xTWM2OD1zMD60NFch|ryP MYXTRW5ITVJ?
EW-3 NWDt[HdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLCOotKSzVyPUGwMlYzQDlizszN MmPZV2FPT0WU
KY821 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHEZmV3UUN3ME2xNE44PjNizszN MVzTRW5ITVJ?
NCI-SNU-1 M{PROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFzLkCyNVch|ryP MYPTRW5ITVJ?
HCC2218 NHfTNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zmcGlEPTB;MUGuN|k5PiEQvF2= M4rr[XNCVkeHUh?=
IM-9 NVrMfop5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TxdWlEPTB;MUGuOVExPiEQvF2= NFHNVJRUSU6JRWK=
NCI-H889 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DTe2lEPTB;MUGuOVMyOyEQvF2= NXrLc4NpW0GQR1XS
HDLM-2 M1j2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF{LkSxOVkh|ryP NUDNS21{W0GQR1XS
LB2518-MEL Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF{Lk[4NVUh|ryP MW\TRW5ITVJ?
NCI-H23 NFTyW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fRXWlEPTB;MUOuNlQzPSEQvF2= NYnUPFBuW0GQR1XS
NB17 NXPhR5FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnETWM2OD1zMz60OVc6KM7:TR?= M4G1T3NCVkeHUh?=
NCI-H322M M1;sc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF2LkSwOlgh|ryP NYDmPW1jW0GQR1XS
SUP-T1 NUX1VYkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPBdGxKSzVyPUG0MlQyOyEQvF2= MU\TRW5ITVJ?
ES3 NF:wRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O3XmlEPTB;MUWuNFcxOyEQvF2= MWDTRW5ITVJ?
ES5 M2nsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fZb2lEPTB;MUWuNFc5PyEQvF2= NHz6UGRUSU6JRWK=
NCI-H1650 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rmVWlEPTB;MUWuOFk4QSEQvF2= NVjPTllsW0GQR1XS
NCI-H226 MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnMTWM2OD1zNT64O|Y5KM7:TR?= NFKzdGxUSU6JRWK=
COR-L88 NELSbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PQe2lEPTB;MU[uN|E1KM7:TR?= NGj3ZnVUSU6JRWK=
SCC-15 M3jsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnIcW1KSzVyPUG2MlM5PjlizszN M3TUSXNCVkeHUh?=
GOTO M3jYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF4LkS3PVMh|ryP NFrQPW1USU6JRWK=
SIMA NV7wT5NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF4LkS4NFIh|ryP NY\RZ|N7W0GQR1XS
NCI-H1299 MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF5LkG1PVEh|ryP Ml\uV2FPT0WU
NCI-H1581 NXftSIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jMNWlEPTB;MUeuOFIyQSEQvF2= MWjTRW5ITVJ?
MHH-NB-11 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzyNWlUUUN3ME2xO{46Pjh|IN88US=> NV[5XWtYW0GQR1XS
MFM-223 NVj4[3pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF6LkC1N|gh|ryP NXnVbpRVW0GQR1XS
ES7 NF\vOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF6LkW0N|Eh|ryP NGP3bGxUSU6JRWK=
JVM-3 NUTIUpR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfO[5hKSzVyPUG4MlcyPyEQvF2= MkGzV2FPT0WU
RL NEfzWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHYTWM2OD1{MD6zPFgh|ryP M37LbXNCVkeHUh?=
EC-GI-10 NX\y[5BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHOe4lkUUN3ME2yNU4zODRzIN88US=> NXrJR4tNW0GQR1XS
LNCaP-Clone-FGC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULodHBJUUN3ME2yNU43PzZ6IN88US=> MX;TRW5ITVJ?
IMR-5 NYSwVZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C4UmlEPTB;MkGuPFQ6PCEQvF2= NYPNOYZSW0GQR1XS
KP-N-YS NYDydZpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj0[IdrUUN3ME2yNU45PzVizszN MYHTRW5ITVJ?
Mo-T NGq5T3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG3TWM2OD1{Mj6yNVg2KM7:TR?= NXjIUWtXW0GQR1XS
NCI-H128 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmybZBKSzVyPUKzMlU5PTNizszN NGDkbINUSU6JRWK=
RH-1 M2LrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PLdmlEPTB;MkOuO|g3PiEQvF2= M2rCO3NCVkeHUh?=
NCI-H2171 NX;TcnZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj3RZB7UUN3ME2yOE4zPDh3IN88US=> NITETWJUSU6JRWK=
RPMI-8866 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP2R2tKSzVyPUK2Mlc1OiEQvF2= MoLmV2FPT0WU
SK-N-FI NIjJSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33MO2lEPTB;MkeuN|gyOSEQvF2= M1e2VnNCVkeHUh?=
LOXIMVI MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TY[mlEPTB;MkeuPFA2OSEQvF2= NWD5SWE2W0GQR1XS
P31-FUJ MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv6SFdKSzVyPUOxMlU{PzRizszN M1L5WHNCVkeHUh?=
KMS-12-PE M{\r[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1POZmlEPTB;NEmuOVMxOiEQvF2= M{\3c3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID